[go: up one dir, main page]

NO20014131L - Epitopes or mimotopes derived from C-epsilon-3 or C-epsilon-4 domains from IgE, antagonists thereof, and derester therapeutic applications - Google Patents

Epitopes or mimotopes derived from C-epsilon-3 or C-epsilon-4 domains from IgE, antagonists thereof, and derester therapeutic applications

Info

Publication number
NO20014131L
NO20014131L NO20014131A NO20014131A NO20014131L NO 20014131 L NO20014131 L NO 20014131L NO 20014131 A NO20014131 A NO 20014131A NO 20014131 A NO20014131 A NO 20014131A NO 20014131 L NO20014131 L NO 20014131L
Authority
NO
Norway
Prior art keywords
epsilon
ige
epitopes
domains
derester
Prior art date
Application number
NO20014131A
Other languages
Norwegian (no)
Other versions
NO20014131D0 (en
Inventor
Martin Friede
Sean Mason
William Gordon Turnell
Marcelle Paulette Van Mechelen
Carlota Vinals Y De Bassols
Original Assignee
Peptide Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9904408.3A external-priority patent/GB9904408D0/en
Priority claimed from GBGB9917144.9A external-priority patent/GB9917144D0/en
Priority claimed from GBGB9918599.3A external-priority patent/GB9918599D0/en
Priority claimed from GBGB9918601.7A external-priority patent/GB9918601D0/en
Priority claimed from GBGB9918598.5A external-priority patent/GB9918598D0/en
Priority claimed from GBGB9918606.6A external-priority patent/GB9918606D0/en
Priority claimed from GBGB9918604.1A external-priority patent/GB9918604D0/en
Priority claimed from GBGB9925618.2A external-priority patent/GB9925618D0/en
Application filed by Peptide Therapeutics Ltd filed Critical Peptide Therapeutics Ltd
Publication of NO20014131D0 publication Critical patent/NO20014131D0/en
Publication of NO20014131L publication Critical patent/NO20014131L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse vedrører nye medikamenter for behandling, forebygging og forbedring av allergisk sykdom. Spesielt er de nye medikamentene epitoper eller mimo-toper avledet fra Ce3- eller Ce4-domenene til IgE. Disse nye regionene kan være mål for både passiv og aktiv immunprofylakse eller immunterapi. Oppfinnelsen vedrører ytterligere fremgangsmåter for produksjon av medikamenter, farmasøytisk sammenset-ning inneholdende disse og deres anvendelse i medisin. Også et aspekt for foreliggende oppfinnelse er ligander, spesielt monoklonale antistoffer, som er istand til å binde til IgE-regionene i den foreliggende oppfinnelsen, og deres anvendelse i medisin som passiv immunterapi eller immunprofylakse.The present invention relates to new medicaments for the treatment, prevention and improvement of allergic disease. In particular, the new drugs are epitopes or mimo-tops derived from the Ce3 or Ce4 domains of IgE. These new regions may be targets for both passive and active immunoprophylaxis or immunotherapy. The invention further relates to processes for the manufacture of medicaments, pharmaceutical compositions containing them and their use in medicine. Also an aspect of the present invention are ligands, especially monoclonal antibodies, which are capable of binding to the IgE regions of the present invention, and their use in medicine as passive immunotherapy or immunoprophylaxis.

NO20014131A 1999-02-25 2001-08-24 Epitopes or mimotopes derived from C-epsilon-3 or C-epsilon-4 domains from IgE, antagonists thereof, and derester therapeutic applications NO20014131L (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GBGB9904408.3A GB9904408D0 (en) 1999-02-25 1999-02-25 Vaccine
GBGB9917144.9A GB9917144D0 (en) 1999-07-21 1999-07-21 Vaccine
GBGB9918599.3A GB9918599D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918601.7A GB9918601D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918598.5A GB9918598D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918606.6A GB9918606D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9918604.1A GB9918604D0 (en) 1999-08-07 1999-08-07 Novel peptides
GBGB9925618.2A GB9925618D0 (en) 1999-10-29 1999-10-29 Vaccine
PCT/EP2000/001456 WO2000050461A1 (en) 1999-02-25 2000-02-22 Epitopes or mimotopes derived from the c-epsilon-3 or c-epsilon-4 domains of ige, antagonists thereof, and their therapeutic uses

Publications (2)

Publication Number Publication Date
NO20014131D0 NO20014131D0 (en) 2001-08-24
NO20014131L true NO20014131L (en) 2001-10-02

Family

ID=27571340

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014131A NO20014131L (en) 1999-02-25 2001-08-24 Epitopes or mimotopes derived from C-epsilon-3 or C-epsilon-4 domains from IgE, antagonists thereof, and derester therapeutic applications

Country Status (18)

Country Link
EP (1) EP1155038A1 (en)
JP (1) JP2002537403A (en)
KR (1) KR20020007314A (en)
CN (1) CN1520423A (en)
AR (1) AR029619A1 (en)
AU (1) AU3281100A (en)
CA (1) CA2363641A1 (en)
CO (1) CO5231139A1 (en)
CZ (1) CZ20013081A3 (en)
HK (1) HK1043134A1 (en)
HU (1) HUP0105490A3 (en)
IL (1) IL145025A0 (en)
MX (1) MXPA01008612A (en)
NO (1) NO20014131L (en)
NZ (1) NZ513680A (en)
PL (1) PL350992A1 (en)
TR (1) TR200102493T2 (en)
WO (1) WO2000050461A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001045745A2 (en) * 1999-12-21 2001-06-28 Acambis Research Limited A reversible linkage technology for controlled conjugation
AU2001252458A1 (en) 2000-05-05 2001-11-20 Martin Bachmann Molecular antigen arrays and vaccines
GB0026334D0 (en) * 2000-10-27 2000-12-13 Smithkline Beecham Biolog Vaccine
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
JP2003047482A (en) * 2001-05-22 2003-02-18 Pfizer Prod Inc IgE VACCINE FREE FROM ANAPHYLAXIS-INDUCING PROPERTY
ATE447967T1 (en) 2001-09-14 2009-11-15 Cytos Biotechnology Ag PACKAGING OF IMMUNO-STIMULATIVE CPG IN VIRUS-LIKE PARTICLES: PRODUCTION METHOD AND USE
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
GB0209878D0 (en) * 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
RU2324704C2 (en) 2002-07-17 2008-05-20 Цитос Байотекнолоджи Аг Antigen molecular massifs
EP2392345A3 (en) 2002-07-18 2012-03-07 Cytos Biotechnology AG Hapten-carrier conjugates comprising virus like particles and uses thereof
RU2450827C2 (en) 2002-07-19 2012-05-20 Цитос Биотехнологи Аг Vaccine compositions containing beta 1-6 amyloid antigen array
JP5022028B2 (en) 2003-03-26 2012-09-12 サイトス・バイオテクノロジー・アクチェンゲゼルシャフト Melan-A peptide analog-virus-like particle conjugate
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
CN102702359A (en) * 2004-02-02 2012-10-03 泰勒公司 Identification of novel igE epitopes
GB0424563D0 (en) 2004-11-05 2004-12-08 Novartis Ag Organic compounds
CA2624081C (en) 2005-09-29 2014-09-16 Medimmune, Inc. Method of identifying membrane ig specific antibodies and use thereof for targeting immunoglobulin-producing precursor cells
EP1973608A1 (en) 2005-12-14 2008-10-01 Cytos Biotechnology AG Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
NZ573622A (en) 2006-06-12 2011-12-22 Cytos Biotechnology Ag Processes for packaging oligonucleotides into virus-like particles of rna bacteriophages
EP2865389A1 (en) * 2008-12-09 2015-04-29 Pfizer Vaccines LLC IgE CH3 peptide vaccine
CA2800774A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
JP5918851B2 (en) * 2012-06-18 2016-05-18 日本全薬工業株式会社 IgE peptide vaccine
WO2019194656A1 (en) * 2018-04-06 2019-10-10 (주)에스엘에스바이오 Novel epitope of immunoglobulin e, antibody binding thereto, and kit for analyzing immunoglobulin e in sample containing same
US20240245190A1 (en) 2023-01-19 2024-07-25 Sharkninja Operating Llc Identification of hair care appliance attachments
EP4651762A1 (en) 2023-01-19 2025-11-26 SharkNinja Operating LLC Hair care appliance with powered attachment
JP7678465B1 (en) * 2023-11-09 2025-05-16 株式会社ファンペップ Vaccine composition for inducing anti-IgE antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02229200A (en) * 1989-02-28 1990-09-11 Dainippon Pharmaceut Co Ltd Peptide having anti-allergic activity
ES2193136T3 (en) * 1991-08-14 2003-11-01 Genentech Inc IMMUNOGLUBINE VARIANTS FOR SPECIFIC RECEIVERS OF FC EPSILON.
EP0885244B2 (en) * 1996-03-01 2008-04-16 Novartis AG Peptide immunogens for vaccination against and treatment of allergy
AU6532498A (en) * 1996-12-06 1998-06-29 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Inhibition of ige-mediated allergies by a human ige-derived oligopeptide
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate

Also Published As

Publication number Publication date
CN1520423A (en) 2004-08-11
EP1155038A1 (en) 2001-11-21
WO2000050461A1 (en) 2000-08-31
CO5231139A1 (en) 2002-12-27
NO20014131D0 (en) 2001-08-24
MXPA01008612A (en) 2003-06-24
TR200102493T2 (en) 2002-02-21
JP2002537403A (en) 2002-11-05
AR029619A1 (en) 2003-07-10
IL145025A0 (en) 2002-06-30
AU3281100A (en) 2000-09-14
HUP0105490A2 (en) 2002-04-29
HK1043134A1 (en) 2002-09-06
HUP0105490A3 (en) 2002-05-28
CZ20013081A3 (en) 2002-02-13
CA2363641A1 (en) 2000-08-31
PL350992A1 (en) 2003-02-24
KR20020007314A (en) 2002-01-26
NZ513680A (en) 2001-09-28

Similar Documents

Publication Publication Date Title
NO20014131L (en) Epitopes or mimotopes derived from C-epsilon-3 or C-epsilon-4 domains from IgE, antagonists thereof, and derester therapeutic applications
NO20053920L (en) Preparation and treatment of demyelination diseases and paralysis in the administration of remyelination agents.
DE60028970D1 (en) AT HER2 BINDING PEPTIDE COMPOUNDS
ATE409181T1 (en) PROTEOMIMETIC COMPOUNDS AND METHODS
MA31899B1 (en) Monoclonal antibodies are associated with hgm-csf and the medical structures they contain
UA90457C2 (en) Human monoclonal antibody that specifically binds to human m-csf
WO2006002177A3 (en) Interferon alpha receptor 1 antibodies and their uses
GEP20084484B (en) Antibodies to insulin-like growth factor i receptor
EA201100546A1 (en) POLYPEPTIDES, VARIABLE DOMAINS OF ANTIBODIES AND ANTAGONISTS
BRPI0407058A (en) Methods of prophylaxis and treatment of a disease, pharmaceutical composition, and use of a fragment
CY1112376T1 (en) 2,3,4,9-tetrahydro-1H-carvasol derivative as CRTH2 receptor antagonists
BR0314797A (en) Pyrimidineamide derivatives and their use
Perego et al. Current and emerging biologics for the treatment of hereditary angioedema
Zinkhan et al. On the role of allergen-specific IgG subclasses for blocking human basophil activation
AU6819600A (en) Use of cd28 specific monoclonal antibodies for producing a pharmaceutical composition for treating virus infections
ATE235551T1 (en) LIGAND (TIE LIGAND-4) FROM TIE-2 RECEPTOR AND ITS USES
MXPA01008613A (en) Epitopes or mimotopes derived from the c-epsilon-2 domain of ige, antagonists thereof, and their therapeutic uses.
TR200103638T2 (en) IL-8 Receptor antagonists
WO2003092714A3 (en) Peptide variants of ige constrained by beta-lactam bond
WO2002034288A8 (en) Vaccine for treating allergy
WO2004110355A3 (en) Compositions and methods including a recombinant human mab that promotes cns remyelination
Ohanjanian et al. An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis
EA200702634A1 (en) HUMANIZED ANTIBODIES SPECIFIC FOR NOGO-A AND THEIR PHARMACEUTICAL APPLICATIONS
ATE265225T1 (en) PHARMACEUTICAL PREPARATION CONTAINING A RECEPTOR ANTAGONIST FOR THE TREATMENT OF BLOOD CLOTTING DISORDERS
ATE378068T1 (en) COMBINATION OF COMPOUNDS WHICH INHIBIT THE BIOLOGICAL EFFECTS OF TNF-ALPHA AND CD95L IN ONE MEDICINAL PRODUCT

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application